{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:41:47Z","timestamp":1789094507385,"version":"build-2803163510"},"reference-count":143,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science Centre in Poland","award":["2023\/51\/D\/NZ5\/00586"],"award-info":[{"award-number":["2023\/51\/D\/NZ5\/00586"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Bladder cancer (BC) is one of the most common malignant neoplasms of the genitourinary system. Traditional BC therapies include chemotherapy, targeted therapy, and immunotherapy. However, limitations such as lack of specificity, cytotoxicity, and multidrug resistance pose serious challenges to the benefits of BC therapies. Consequently, current studies focus on the search for new therapeutic solutions. In recent years, there has been a growing interest in using nanotechnology in the treatment of both non-invasive (NMIBC) and invasive bladder cancer (MIBC). Nanotechnology is based on the use of both organic molecules (chitosan, liposomes) and inorganic molecules (superparamagnetic iron oxide nanoparticles) as carriers of active substances. The main aim of such molecules is the targeted transport and prolonged retention of the drug in the target tissue, which increases the therapeutic efficacy of the active substance. This review discusses the numerous types of nanoparticles (including chitosan, polymeric nanoparticles, liposomes, and protein nanoparticles), targeting mechanisms, and approved nanotherapeutics with oncological implications in cancer treatment. We also present nanoformulation applications in phototherapy, gene therapy, and immunotherapy. Moreover, we summarise the current perspectives, advantages, and challenges in clinical translation.<\/jats:p>","DOI":"10.3390\/ijms251910388","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T03:44:13Z","timestamp":1727408653000},"page":"10388","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Nanomedicine in Bladder Cancer Therapy"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9596-9892","authenticated-orcid":false,"given":"Adrianna","family":"Winnicka","sequence":"first","affiliation":[{"name":"Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 90-136 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Brzeszczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 90-136 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1197-1713","authenticated-orcid":false,"given":"Joanna","family":"Saluk","sequence":"additional","affiliation":[{"name":"Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 90-136 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0590-6966","authenticated-orcid":false,"given":"Paulina","family":"Wigner-Jeziorska","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-136 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dobruch, J., and Oszczud\u0142owski, M. (2021). Bladder Cancer: Current Challenges and Future Directions. Medicina, 57.","DOI":"10.3390\/medicina57080749"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, Screening, and Prevention of Bladder Cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_3","unstructured":"World Cancer Research Fund International (2024, August 20). Bladder Cancer Statistics. Available online: https:\/\/www.wcrf.org\/cancer-trends\/bladder-cancer-statistics\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Barber, N., and Ali, A. (2022). Chapter 3\u2014The Etiology of Bladder Cancer. Urologic Cancers, Exon Publications.","DOI":"10.36255\/exon-publications-urologic-cancers"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","article-title":"Bladder cancer","volume":"374","author":"Kaufman","year":"2009","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA A Cancer J. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Xu, Y., Luo, C., Wang, J., Chen, L., Chen, J., Chen, T., and Zeng, Q. (2021). Application of nanotechnology in the diagnosis and treatment of bladder cancer. J. Nanobiotechnol., 19.","DOI":"10.1186\/s12951-021-01104-y"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.5603\/NJO.2013.0020","article-title":"Zastosowanie nanocz\u0105steczek w leczeniu i diagnostyce nowotwor\u00f3w","volume":"63","author":"Olszewska","year":"2013","journal-title":"Nowotwory. J. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Najahi-Missaoui, W., Arnold, R.D., and Cummings, B.S. (2020). Safe Nanoparticles: Are We There Yet?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010385"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4236\/jct.2011.23045","article-title":"Nanoparticles in Drug Delivery and Cancer Therapy: The Giant Rats Tail","volume":"2","author":"Prabhu","year":"2011","journal-title":"J. Cancer Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.surneu.2003.09.036","article-title":"Introduction to nanotechnology and its applications to medicine","volume":"61","author":"Silva","year":"2004","journal-title":"Surg. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fmolb.2020.00193","article-title":"Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance","volume":"7","author":"Yao","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Singh, P., Pandit, S., Mokkapati, V., Garg, A., Ravikumar, V., and Mijakovic, I. (2018). Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19071979"},{"key":"ref_18","unstructured":"PDQ Adult Treatment Editorial Board (2023). Bladder Cancer Treatment (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries, National Cancer Institute."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5644\/ama2006-124.332","article-title":"New Insights into the Diagnosis, Molecular Taxonomy, and Treatment of Bladder Cancer","volume":"50","author":"Ulamec","year":"2021","journal-title":"Acta Medica Acad."},{"key":"ref_20","first-page":"507","article-title":"Bladder Cancer: Diagnosis and Treatment","volume":"96","author":"DeGeorge","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.21037\/tau.2019.09.38","article-title":"Transurethral resection of bladder tumour (TURBT)","volume":"9","author":"Kim","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"ref_22","first-page":"CD009294","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"2021","author":"Han","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11912-021-01091-1","article-title":"Approaches to Non-Muscle-Invasive Bladder Cancer","volume":"23","author":"Slovacek","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Audisio, A., Buttigliero, C., Delcuratolo, M.D., Parlagreco, E., Audisio, M., Ungaro, A., Di Stefano, R.F., Di Prima, L., Turco, F., and Tucci, M. (2022). New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond. Cells, 11.","DOI":"10.3390\/cells11030357"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2217\/nnm.14.212","article-title":"Nanotechnology in Bladder Cancer: Current State of Development and Clinical Practice","volume":"10","author":"Tomlinson","year":"2015","journal-title":"Nanomedicine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial","volume":"13","author":"Herr","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0022-5347(17)40575-1","article-title":"Superficial Bladder Cancer Treated with Bacillus Calmette-Guerin: A Multivariate Analysis of Factors Affecting Tumor Progression","volume":"141","author":"Herr","year":"1989","journal-title":"J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1590\/s1677-5538.ibju.2020.99.01","article-title":"Bladder preservation in muscle-invasive bladder cancer: A comprehensive review","volume":"46","author":"Hamad","year":"2020","journal-title":"Int. Braz. J. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kong, C., Zhang, S., Lei, Q., and Wu, S. (2022). State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer. Biosensors, 12.","DOI":"10.3390\/bios12100796"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrurol.2017.82","article-title":"Landmarks in the treatment of muscle-invasive bladder cancer","volume":"14","author":"Lobo","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, The Australian Bladder Cancer Study Group, The National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, and Club Urologico Espanol de Tratamiento Oncologico Group (2011). International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial. J. Clin. Oncol., 29, 2171\u20132177.","DOI":"10.1200\/JCO.2010.32.3139"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.trecan.2019.05.011","article-title":"Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer","volume":"5","author":"Ghandour","year":"2019","journal-title":"Trends Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ucl.2015.02.002","article-title":"Trimodality Therapy in Bladder Cancer: Who, what, and when?","volume":"42","author":"Premo","year":"2015","journal-title":"Urol. Clin. N. Am."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kubrak, T., Karaku\u0142a, M., Czop, M., Kawczyk-Krupka, A., and Aebisher, D. (2022). Advances in Management of Bladder Cancer\u2014The Role of Photodynamic Therapy. Molecules, 27.","DOI":"10.3390\/molecules27030731"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.biopha.2018.07.049","article-title":"Photodynamic therapy\u2014Mechanisms, photosensitizers and combinations","volume":"106","author":"Kwiatkowski","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Song, F.-X., Xu, X., Ding, H., Yu, L., Huang, H., Hao, J., Wu, C., Liang, R., and Zhang, S. (2023). Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer. Biosensors, 13.","DOI":"10.3390\/bios13010106"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/jnci\/90.12.889","article-title":"Photodynamic Therapy","volume":"90","author":"Dougherty","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2010.08.031","article-title":"Intravesical drug delivery: Challenges, current status, opportunities and novel strategies","volume":"148","author":"GuhaSarkar","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Yu, C., Wang, S., Lai, W.-F., and Zhang, D. (2023). The Progress of Chitosan-Based Nanoparticles for Intravesical Bladder Cancer Treatment. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010211"},{"key":"ref_43","unstructured":"(2020, March 07). U.S. National Library of Medicine. Clinical Trials.gov, Available online: https:\/\/www.clinicaltrials.gov\/."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"115004","DOI":"10.1016\/j.carbpol.2019.115004","article-title":"Advances in chitosan-based nanoparticles for oncotherapy","volume":"222","author":"Zhang","year":"2019","journal-title":"Carbohydr. Polym."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1166\/jbn.2016.2228","article-title":"Functional Chitosan Nanoparticles in Cancer Treatment","volume":"12","author":"Fu","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Jafernik, K., \u0141adniak, A., Blicharska, E., Czarnek, K., Ekiert, H., Wi\u0105cek, A.E., and Szopa, A. (2023). Chitosan-Based Nanoparticles as Effective Drug Delivery Systems\u2014A review. Molecules, 28.","DOI":"10.3390\/molecules28041963"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Rizeq, B.R., Younes, N.N., Rasool, K., and Nasrallah, G.K. (2019). Synthesis, Bioapplications, and Toxicity Evaluation of Chitosan-Based Nanoparticles. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225776"},{"key":"ref_48","first-page":"6493","article-title":"Design and evaluation of an intravesical delivery system for superficial bladder cancer: Preparation of gemcitabine HCl-loaded chitosan\u2013thioglycolic acid nanoparticles and comparison of chitosan\/poloxamer gels as carriers","volume":"10","author":"Karavana","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1021\/acsabm.8b00501","article-title":"Paclitaxel\/Chitosan Nanosupensions Provide Enhanced Intravesical Bladder Cancer Therapy with Sustained and Prolonged Delivery of Paclitaxel","volume":"1","author":"Liu","year":"2018","journal-title":"ACS Appl. Bio Mater."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1464-410X.2008.07571.x","article-title":"Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer","volume":"101","author":"Hadaschik","year":"2008","journal-title":"BJU Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11095-012-0889-z","article-title":"Application of Drug Nanocrystal Technologies on Oral Drug Delivery of Poorly Soluble Drugs","volume":"30","author":"Gao","year":"2012","journal-title":"Pharm. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jconrel.2020.03.028","article-title":"Mucoadhesive nanoparticles based on ROS activated gambogic acid prodrug for safe and efficient intravesical instillation chemotherapy of bladder cancer","volume":"324","author":"Xu","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.12.015","article-title":"Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors","volume":"371","author":"Bilensoy","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2007.12.014","article-title":"Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice","volume":"127","author":"Kim","year":"2008","journal-title":"J. Control. Release"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jconrel.2009.06.015","article-title":"Hydrotropic oligomer-conjugated glycol chitosan as a carrier of paclitaxel: Synthesis, characterization, and in vivo biodistribution","volume":"140","author":"Saravanakumar","year":"2009","journal-title":"J. Control. Release"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"112089","DOI":"10.1016\/j.msec.2021.112089","article-title":"Chitosan and chitosan\/PEG nanoparticles loaded with indole-3-carbinol: Characterization, computational study and potential effect on human bladder cancer cells","volume":"124","author":"Melo","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/B978-0-12-416020-0.00007-3","article-title":"Polymer nanoparticles","volume":"104","author":"Lu","year":"2011","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Madkour, L.H. (2019). Nanoparticle and polymeric nanoparticle-based targeted drug delivery systems. Nucleic Acids as Gene Anticancer Drug Delivery Therapy, Academic Press.","DOI":"10.1016\/B978-0-12-819777-6.00013-5"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3109\/03639049809108571","article-title":"Preparation Techniques and Mechanisms of Formation of Biodegradable Nanoparticles from Preformed Polymers","volume":"24","author":"Fessi","year":"1998","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/cancers5010296","article-title":"Nanomaterials and Autophagy: New Insights in Cancer Treatment","volume":"5","author":"Panzarini","year":"2013","journal-title":"Cancers"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40846-015-0060-5","article-title":"Review: Application of Nanoparticles in Urothelial Cancer of the Urinary Bladder","volume":"35","author":"Chen","year":"2015","journal-title":"J. Med. Biol. Eng."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Gagliardi, A., Giuliano, E., Venkateswararao, E., Fresta, M., Bulotta, S., Awasthi, V., and Cosco, D. (2021). Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.601626"},{"key":"ref_63","first-page":"74","article-title":"New frontiers in nanotechnology for cancer treatment","volume":"26","author":"Alexis","year":"2008","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1023\/A:1011922819926","article-title":"Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration","volume":"15","author":"Gref","year":"1998","journal-title":"Pharm. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0168-3659(01)00397-2","article-title":"Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA","volume":"75","author":"Perez","year":"2001","journal-title":"J. Control. Release"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/jcb.20796","article-title":"Engineered nanoparticles as precise drug delivery systems","volume":"97","author":"Yih","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature02388","article-title":"Designing materials for biology and medicine","volume":"428","author":"Langer","year":"2004","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/263797a0","article-title":"Polymers for the sustained release of proteins and other macromolecules","volume":"263","author":"Langer","year":"1976","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s11095-007-9284-6","article-title":"Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery","volume":"24","author":"Vyas","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.1158\/1078-0432.CCR-17-1082","article-title":"Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non\u2013Muscle-Invasive Bladder Cancer","volume":"23","author":"Kates","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1021\/bm300739w","article-title":"Polymeric Nanoparticles with Encapsulated Superparamagnetic Iron Oxide and Conjugated Cisplatin for Potential Bladder Cancer Therapy","volume":"13","author":"Huang","year":"2012","journal-title":"Biomacromolecules"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1517\/13543784.2015.1109626","article-title":"Docetaxel for the treatment of bladder cancer","volume":"24","author":"Albany","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1158\/1078-0432.CCR-10-2981","article-title":"In vivo Evaluation of Mucoadhesive Nanoparticulate Docetaxel for Intravesical Treatment of Non\u2013Muscle-Invasive Bladder Cancer","volume":"17","author":"Mugabe","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8970135","DOI":"10.34133\/2020\/8970135","article-title":"Synergistically Enhanced Mucoadhesive and Penetrable Polypeptide Nanogel for Efficient Drug Delivery to Orthotopic Bladder Cancer","volume":"2020","author":"Guo","year":"2020","journal-title":"Research"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1002\/mco2.339","article-title":"Lipid-based nanoparticles as drug delivery systems for cancer immunotherapy","volume":"4","author":"Hao","year":"2023","journal-title":"MedComm"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","article-title":"Liposomes: Advancements and innovation in the manufacturing process","volume":"154-155","author":"Shah","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1586\/14737175.6.10.1495","article-title":"Advances in strategies to improve drug delivery to brain tumors","volume":"6","author":"Newton","year":"2006","journal-title":"Expert Rev. Neurother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1039\/c3tb21238f","article-title":"Liposome-like nanostructures for drug delivery","volume":"1","author":"Gao","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0022-2836(64)80115-7","article-title":"Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope","volume":"8","author":"Bangham","year":"1964","journal-title":"J. Mol. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/187221050902150819151721","article-title":"Recent Progress in Liposome Production, Relevance to Drug Delivery and Nanomedicine","volume":"9","author":"Koynova","year":"2015","journal-title":"Recent Pat. Nanotechnol."},{"key":"ref_82","first-page":"65","article-title":"Liposomes as targetable drug carriers","volume":"2","author":"Torchilin","year":"1985","journal-title":"Crit. Rev. Ther. Drug. Carrier Syst."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.2174\/1381612827666210830095941","article-title":"Multivesicular Liposome: A Lipid-based Drug Delivery System for Efficient Drug Delivery","volume":"27","author":"Gorain","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijpharm.2017.08.120","article-title":"Advances in intravesical drug delivery systems to treat bladder cancer","volume":"532","author":"Kolawole","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejps.2017.09.039","article-title":"Mucoadhesive maleimide-functionalised liposomes for drug delivery to urinary bladder","volume":"111","author":"Kaldybekov","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ghoran, S.H., Calcaterra, A., Abbasi, M., Taktaz, F., Nieselt, K., and Babaei, E. (2022). Curcumin-Based Nanoformulations: A Promising Adjuvant towards Cancer Treatment. Molecules, 27.","DOI":"10.3390\/molecules27165236"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2174\/1381612829666230331084848","article-title":"Selective Cellular Uptake and Cytotoxicity of Curcumin-encapsulated SPC and HSPC Liposome Nanoparticles on Human Bladder Cancer Cells","volume":"29","author":"Gholami","year":"2023","journal-title":"Curr. Pharm. Des."},{"key":"ref_88","first-page":"295","article-title":"Randomized, Double-blind Pilot Study of Nanocurcumin in Bladder Cancer Patients Receiving Induction Chemotherapy","volume":"18","author":"Sandoughdaran","year":"2021","journal-title":"Urol. J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mtchem.2018.05.002","article-title":"Biopolymer based nanomaterials in drug delivery systems: A review","volume":"9","author":"Jacob","year":"2018","journal-title":"Mater. Today Chem."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Hong, S., Choi, D.W., Kim, H.N., Park, C.G., Lee, W., and Park, H.H. (2020). Protein-Based Nanoparticles as Drug Delivery Systems. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12070604"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Kianfar, E. (2021). Protein nanoparticles in drug delivery: Animal protein, plant proteins and protein cages, albumin nanoparticles. J. Nanobiotechnol., 19.","DOI":"10.1186\/s12951-021-00896-3"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.juro.2010.11.091","article-title":"Paclitaxel Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy","volume":"185","author":"Lu","year":"2011","journal-title":"J. Urol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-18-3267","article-title":"CD47-Targeted Near-Infrared Photoimmunotherapy for Human Bladder Cancer","volume":"25","author":"Kiss","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Mullapudi, S.S., Rahmat, J.N., Mahendran, R., Lim, Y.K., Ong, L.T., Wong, K.Y., Chiong, E., Kang, E.-T., and Neoh, K.G. (2022). Tumor-targeting albumin nanoparticles as an efficacious drug delivery system and potential diagnostic tool in non-muscle-invasive bladder cancer therapy. Nanomed. Nanotechnol. Biol. Med., 46.","DOI":"10.1016\/j.nano.2022.102600"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.2147\/IJN.S269321","article-title":"Pathological Mechanism of Photodynamic Therapy and Photothermal Therapy Based on Nanoparticles","volume":"15","author":"Hou","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/00365599.2012.713000","article-title":"Photodynamic effect of 5-aminolevulinic acid-loaded nanoparticles on bladder cancer cells: A preliminary investigation","volume":"47","author":"Yan","year":"2013","journal-title":"Scand. J. Urol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.biomaterials.2016.07.026","article-title":"Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer","volume":"104","author":"Lin","year":"2016","journal-title":"Biomaterials"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1476-4598-10-9","article-title":"Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand","volume":"10","author":"Lin","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1566523033347499","article-title":"Advances in Gene Therapy for Bladder Cancer","volume":"3","author":"Irie","year":"2003","journal-title":"Curr. Gene Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MOU.0b013e32830b86e3","article-title":"Gene therapy in bladder cancer","volume":"18","author":"Bochner","year":"2008","journal-title":"Curr. Opin. Urol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1586\/14737140.1.4.531","article-title":"Gene therapy for superficial bladder cancer","volume":"1","author":"Rosser","year":"2001","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Roma-Rodrigues, C., Rivas-Garc\u00eda, L., Baptista, P.V., and Fernandes, A.R. (2020). Gene Therapy in Cancer Treatment: Why Go Nano?. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030233"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Ashrafizadeh, M., Zarrabi, A., Karimi-Maleh, H., Taheriazam, A., Mirzaei, S., Hashemi, M., Hushmandi, K., Makvandi, P., Zare, E.N., and Sharifi, E. (2022). (Nano)platforms in bladder cancer therapy: Challenges and opportunities. Bioeng. Transl. Med., 8.","DOI":"10.1002\/btm2.10353"},{"key":"ref_104","first-page":"433","article-title":"Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer","volume":"6","author":"Liang","year":"2020","journal-title":"Bioact. Mater."},{"key":"ref_105","first-page":"e36\u201341","article-title":"Bladder cancer detection with urinary survivin, an inhibitor of apoptosis","volume":"7","author":"Jennifer","year":"2002","journal-title":"Front. Biosci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1535-7163.MCT-13-0502","article-title":"Surface-Modified Nanoparticles Enhance Transurothelial Penetration and Delivery of Survivin siRNA in Treating Bladder Cancer","volume":"13","author":"Martin","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1039\/D0BM00015A","article-title":"Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy","volume":"8","author":"Ahir","year":"2020","journal-title":"Biomater. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1051\/jbio\/2018028","article-title":"Immunoth\u00e9rapie et cancer de la vessie: \u00c9tat des connaissances actuelles et perspectives futures","volume":"212","author":"Lenfant","year":"2018","journal-title":"Biol. Aujourd\u2019hui"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ucl.2020.10.005","article-title":"The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer","volume":"47","author":"Nair","year":"2020","journal-title":"Urol. Clin. N. Am."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Tian, Y., Liu, Z., Wang, J., Li, L., Wang, F., Zhu, Z., and Wang, X. (2023). Nanomedicine for Combination Urologic Cancer Immunotherapy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020546"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cell.2020.02.001","article-title":"Targeting strategies for tissue-specific drug delivery","volume":"181","author":"Zhao","year":"2020","journal-title":"Cell"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.semcancer.2019.07.023","article-title":"Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects","volume":"69","author":"Khan","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"10156","DOI":"10.1166\/jnn.2015.11690","article-title":"Antitumor Efficacy of Bacillus Calmette-Guerin Loaded Cationic Nanoparticles for Intravesical Immunotherapy of Bladder Tumor Induced Rat Model","volume":"15","author":"Iskit","year":"2015","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2013.12.027","article-title":"Nanoparticulation of BCG-CWS for application to bladder cancer therapy","volume":"176","author":"Nakamura","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1021\/acs.molpharmaceut.1c00448","article-title":"Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer","volume":"18","author":"Zhou","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Roviello, G., Catalano, M., Santi, R., Palmieri, V.E., Vannini, G., Galli, I.C., Buttitta, E., Villari, D., Rossi, V., and Nesi, G. (2021). Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13174411"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/cncy.22603","article-title":"Insights on recent innovations in bladder cancer immunotherapy","volume":"130","author":"Smith","year":"2022","journal-title":"Cancer Cytopathol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Lopez-Beltran, A., Cimadamore, A., Blanca, A., Massari, F., Vau, N., Scarpelli, M., Cheng, L., and Montironi, R. (2021). Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers, 13.","DOI":"10.3390\/cancers13010131"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41389-017-0013-7","article-title":"Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy","volume":"7","author":"Cheng","year":"2018","journal-title":"Oncogenesis"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Li, G., Tao, T., Deng, D., Zhang, S., Chao, Y., Dai, Y., Li, Y., Tao, R., Yuan, S., and Liu, Z. (2022). Collagen-targeted tumor-specific transepithelial penetration enhancer mediated intravesical chemoimmunotherapy for non-muscle-invasive bladder cancer. Biomaterials, 283.","DOI":"10.1016\/j.biomaterials.2022.121422"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Tang, C., Liu, H., Fan, Y., He, J., Li, F., Wang, J., and Hou, Y. (2021). Functional Nanomedicines for Targeted Therapy of Bladder Cancer. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.778973"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Barani, M., Hosseinikhah, S.M., Rahdar, A., Farhoudi, L., Arshad, R., Cucchiarini, M., and Pandey, S. (2021). Nanotechnology in Bladder Cancer: Diagnosis and Treatment. Cancers, 13.","DOI":"10.3390\/cancers13092214"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Erman, A., and Verani\u010d, P. (2018). The Use of Polymer Chitosan in Intravesical Treatment of Urinary Bladder Cancer and Infections. Polymers, 10.","DOI":"10.3390\/polym10030265"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Guo, H., Li, F., Qiu, H., Liu, J., Qin, S., Hou, Y., and Wang, C. (2020). Preparation and Characterization of Chitosan Nanoparticles for Chemotherapy of Melanoma Through Enhancing Tumor Penetration. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00317"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2147\/IJN.S385166","article-title":"A Novel Nanoemulsion Formula for an Improved Delivery of a Thalidomide Analogue to Triple-Negative Breast Cancer; Synthesis, Formulation, Characterization and Molecular Studies","volume":"18","author":"Tawfik","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"ref_127","unstructured":"Priyadarshani, A. (2022). Advantages and Disadvantages of Solid Lipid Nanoparticles. J. Nanomed. Biother. Discov., 12."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1007\/s00289-021-03729-3","article-title":"Nanoemulgel: A promising novel formulation for treatment of skin ailments","volume":"79","author":"Ojha","year":"2022","journal-title":"Polym. Bull."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"104984","DOI":"10.1016\/j.supflu.2020.104984","article-title":"Sustainable technologies for liposome preparation","volume":"165","author":"Leitgeb","year":"2020","journal-title":"J. Supercrit. Fluids"},{"key":"ref_130","first-page":"20180032","article-title":"Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles","volume":"34","author":"Alavi","year":"2019","journal-title":"Drug Metab. Pers. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Waheed, I., Ali, A., Tabassum, H., Khatoon, N., Lai, W.F., and Zhou, X. (2024). Lipid-based nanoparticles as drug delivery carriers for cancer therapy. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1296091"},{"key":"ref_132","first-page":"2733","article-title":"Advanced drug delivery to the lymphatic system: Lipid-based nanoformulations","volume":"8","author":"Mudassir","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1021\/acsbiomaterials.8b01098","article-title":"Protein Nanoparticles: Promising Platforms for Drug Delivery Applications","volume":"4","author":"Jain","year":"2018","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Diaz, D., Care, A., and Sunna, A. (2018). Bioengineering Strategies for Protein-Based Nanoparticles. Genes, 9.","DOI":"10.3390\/genes9070370"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40169-019-0224-y","article-title":"Cell membrane protein functionalization of nanoparticles as a new tumor-targeting strategy","volume":"8","author":"Pasto","year":"2019","journal-title":"Clin. Transl. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.addr.2007.08.044","article-title":"Protein nanoparticles as drug carriers in clinical medicine","volume":"60","author":"Hawkins","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40580-021-00293-4","article-title":"Protein nanoparticles directed cancer imaging and therapy","volume":"9","author":"Miao","year":"2022","journal-title":"Nano Converg."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/toxsci\/kfj122","article-title":"Penetration of intact skin by quantum dots with diverse physicochemical properties","volume":"91","author":"Riviere","year":"2006","journal-title":"Toxicol. Sci. Off. J. Soc. Toxicol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11051-008-9446-4","article-title":"Characterization of size, surface charge, and agglomeration state of nanoparticle dispersions for toxicological studies","volume":"11","author":"Jiang","year":"2009","journal-title":"J. Nanopart. Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2174\/2468187306666160808160330","article-title":"Opportunities and challenges in nano-structure mediated drug delivery: Where do we stand?","volume":"6","author":"Awasthi","year":"2016","journal-title":"Curr. Nanomed."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.biomaterials.2018.06.029","article-title":"NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo","volume":"178","author":"Jia","year":"2018","journal-title":"Biomaterials"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1021\/nl061025k","article-title":"Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm","volume":"6","author":"Xia","year":"2006","journal-title":"Nano Lett."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","article-title":"Nanoparticles for Cancer Therapy: Current Progress and Challenges","volume":"16","author":"Gavas","year":"2021","journal-title":"Nanoscale Res. Lett."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10388\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:04:24Z","timestamp":1760112264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":143,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["ijms251910388"],"URL":"https:\/\/doi.org\/10.3390\/ijms251910388","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}